We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01068418
Recruitment Status : Completed
First Posted : February 15, 2010
Results First Posted : February 14, 2017
Last Update Posted : March 30, 2017
Sponsor:
Information provided by (Responsible Party):
Jonathan S. Williams, MD, MMSc, Brigham and Women's Hospital

Brief Summary:

Hypothesis: Vitamin D supplementation lower renin-angiotensin system activity in obesity.

Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.


Condition or disease Intervention/treatment
Obesity Vitamin D Deficiency Hypertension Dietary Supplement: Vitamin D (cholecalciferol)

Detailed Description:

Vitamin D deficiency and obesity are international epidemics that have both been associated with increased activity of the renin-angiotensin system (RAS). Because increased RAS activity is associated with cardiovascular disease, interventions to lower RAS will have favorable public health impacts.

This study aims to evaluate whether the supplementation of Vitamin D in obese subjects will lower local tissue RAS activity. RAS activity will be evaluated by cross-sectional measurement of RAS components and by quantifying the vascular response to an infusion of angiotensin II. Subjects will be studied while Vitamin D deficient, and will return for repeat study following Vitamin D supplementation, for comparison.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity
Study Start Date : February 2010
Primary Completion Date : September 2011
Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Vitamin D3
15000IU of vitamin D3 daily: open-label, single-arm
Dietary Supplement: Vitamin D (cholecalciferol)
cholecalciferol 15,000 IU daily for 30 days



Primary Outcome Measures :
  1. The Change in the Mean Arterial Blood Pressure in Response to an Infusion of Angiotensin II [ Time Frame: baseline and 1 month following vitamin D3 therapy ]

Secondary Outcome Measures :
  1. The Change in Renal Blood Flow in Response to an Infusion of Angiotensin II [ Time Frame: baseline and 1 month following vitamin D3 therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age < 65,
  • Cr < 1.6,
  • 25-hydroxyvitamin D < 25 ng/mL,
  • BMI > 30 kg/m2,
  • stage I hypertension.

Exclusion Criteria:

  • diabetes,
  • coronary heart disease,
  • heart failure,
  • renal failure,
  • liver failure,
  • hyperparathyroidism,
  • granulomatous disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01068418


Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Jonathan S Williams, MD, MMSc Brigham and Women's Hospital
Study Director: Anand Vaidya, MD Brigham and Women's Hospital

Responsible Party: Jonathan S. Williams, MD, MMSc, Assistant Professor of Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01068418     History of Changes
Other Study ID Numbers: 2009p002062
First Posted: February 15, 2010    Key Record Dates
Results First Posted: February 14, 2017
Last Update Posted: March 30, 2017
Last Verified: March 2017

Keywords provided by Jonathan S. Williams, MD, MMSc, Brigham and Women's Hospital:
Obesity
Renin Angiotensin System
Vitamin D deficiency
Hypertension

Additional relevant MeSH terms:
Hypertension
Obesity
Vitamin D Deficiency
Vascular Diseases
Cardiovascular Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Avitaminosis
Deficiency Diseases
Malnutrition
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents